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Background: Vaccine development has been a priority in the fight against leishmaniases, which 
are vector-borne diseases caused by Leishmania protozoa. Among the different immunization 
strategies employed to date is inoculation of plasmid DNA coding for parasite antigens, 
which has a demonstrated ability to induce humoral and cellular immune responses. In this 
sense, inoculation of plasmid DNA encoding Leishmania kinetoplasmid membrane protein-11 
(KMP-11) was able to confer protection against visceral leishmaniasis. However, recently the 
use of antigen delivery systems such as poly(lactic-co-glycolic acid) (PLGA) nanoparticles has 
also proven effective for eliciting protective immune responses.
Methods: In the present work, we tested two immunization strategies with the goal of obtaining 
protection, in terms of lesion development and parasite load, against cutaneous leishmaniasis 
caused by L. braziliensis. One strategy involved immunization with plasmid DNA encoding 
L. infantum chagasi KMP-11. Alternatively, mice were primed with PLGA nanoparticles 
loaded with the recombinant plasmid DNA and boosted using PLGA nanoparticles loaded 
with recombinant KMP-11.
Results: Both immunization strategies elicited detectable cellular immune responses with 
the presence of both proinflammatory and anti-inflammatory cytokines; mice receiving the 
 recombinant PLGA nanoparticle formulations also demonstrated anti-KMP-11 IgG1 and 
IgG2a. Mice were then challenged with L. braziliensis, in the presence of sand fly saliva. 
Lesion  development was not inhibited following either immunization strategy. However, 
immunization with PLGA nanoparticles resulted in a more prominent reduction in parasite load 
at the infection site when compared with immunization using plasmid DNA alone. This effect 
was associated with a local increase in interferon-gamma and in tumor necrosis factor-alpha. 
Both immunization strategies also resulted in a lower parasite load in the draining lymph nodes, 
albeit not significantly.
Conclusion: Our results encourage the pursuit of immunization strategies employing 
 nanobased delivery systems for vaccine development against cutaneous leishmaniasis caused 
by L.  braziliensis infection.
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Introduction
Leishmaniasis is a group of diseases caused by infection with unicellular protozoan 
parasites of the genus Leishmania, which are transmitted through the bite of an infected 
sand fly. Disease burden remains important, involving 88 countries and 350 million 
people at risk, with 500,000 new cases of visceral leishmaniasis and 1–1.5 million cases 
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of cutaneous leishmaniasis per year.1 Multiple Leishmania 
species are known to cause disease; L. braziliensis inoculation 
into the skin leads to the development of an ulcer with  elevated 
borders and a necrotic center. A chronic inflammatory 
response develops despite the paucity of parasites. In 1%–5% 
of patients, mucocutaneous leishmaniasis may develop, 
and in this case, extensive tissue destruction is observed.2 
Species such as L. infantum chagasi multiply in the spleen 
and liver, causing visceral leishmaniasis. The disease may 
present with acute, subacute, or chronic evolution, but most 
infected individuals remain completely asymptomatic.3 The 
visceral form of leishmaniasis is associated with an estimated 
incidence of 59,000 deaths annually.4 The feasibility of 
preventing Leishmania infection through vaccination is 
supported by the fact that individuals who recover from a 
primary infection are resistant to overt clinical manifestations 
upon reinfection. In general, the key mediator of resistance 
to leishmaniasis is cellular immunity, whereby interferon-
gamma (IFN-γ) produced by CD4+ Th1 cells promotes 
the oxidative burst in phagocytes that host the intracellular 
pathogen, promoting parasite killing.5,6
Vaccination against leishmaniasis has been pursued 
using different strategies, ranging from inoculation of 
virulent parasites (leishmanization) to immunization with 
killed parasite preparations, live attenuated parasites, or 
with recombinant proteins or plasmid DNA coding for 
defined Leishmania antigens.7,8 DNA vaccines encode a 
potent adjuvant, in the form of unmethylated dinucleotides, 
which are able to activate antigen-presenting cells through 
Toll-like receptor 9, stimulating the system towards a 
Th1-type response. DNA vaccination has also been tested 
in heterologous prime-boost vaccination regimes9 in which 
the immune system is primed with DNA and boosted with 
a different formulation of the corresponding antigen. This 
strategy proved effective in models of visceral10–12 and 
cutaneous leishmaniasis.13–15 However, the adjuvant effect 
can also be achieved by encapsulation of antigens into 
biodegradable and biocompatible particles.16 In this sense, 
immunization with antigen-loaded poly(lactic-co-glycolic 
acid) (PLGA) nanoparticles induced potent immune 
responses in different experimental models of disease.17–19 
Similar and encouraging results have been described 
regarding encapsulation of Leishmania antigens and the 
development of leishmaniasis.20,21
The 11 kDa kinetoplastid membrane protein (KMP-11)22 
is a promising vaccine candidate against leishmaniasis 
because it is a strong inducer of IFN-γ production by cells 
from cured patients23 and it is highly conserved among the 
trypanosomatids.24 DNA immunization with KMP-11 was 
able to confer protection against visceral leishmaniasis caused 
by L. donovani25 and against cutaneous leishmaniasis caused 
by L. major, when used in combination with interleukin 
(IL)-12.26 Given that there are few published studies 
regarding vaccine development against L. braziliensis,27 a 
species  prevalent in Brazil and South America, we evaluated 
the ability of KMP-11 to confer protection against cutaneous 
leishmaniasis caused by L. braziliensis, employing two 
strategies. One strategy involved immunization with a naked 
plasmid DNA coding for KMP-11, whereas a parallel strategy 
comprised priming with PLGA nanoparticles loaded with a 
plasmid DNA encoding KMP-11 followed by PLGA nano-
particles loaded with the recombinant KMP-11 protein.
Materials and methods
Mice
Female BALB/c mice (6–8 weeks of age) were obtained from 
the animal facility at Centro de Pesquisas Gonçalo Moniz, 
FIOCRUZ. All mice were maintained under pathogen-free 
conditions. The local Ethics Committee on Animal Care and 
Utilization approved all procedures involving animals.
Plasmid and recombinant protein 
purification
The DNA insert containing the coding region of Leishmania 
KMP-11 was obtained after BamHI/SmaI digestion of the 
pQE-KMP-11 plasmid28 and was subcloned in the BamHI/
EcoRV sites of the pcDNA3 eukaryotic expression plasmid. 
Plasmid DNA (pcDNA3 and pcDNA3-KMP-11) was purified 
using an Endofree Plasmid Giga Kit (Qiagen, Valencia, CA) 
according to the manufacturer’s instructions. The recombinant 
plasmid, pQE30-KMP-11,28 was transformed into Escherichia 
coli. Recombinant protein expression was performed as 
described previously.29 Nonrecombinant pcDNA3, pcDNA3-
KMP-11, and recombinant KMP-11 protein were encapsu-
lated into PLGA nanoparticles, as described below.
Preparation and characterization  
of KMP-11 nanoparticles
Nanoparticles were prepared by employing a solvent 
evaporation process using a Total Recirculation One-Machine 
System, which has been used previously for the encapsulation 
of DNA into PLGA particles.30 Briefly, 100 mg of PLGA 
Resomer 503 copolymer (4% w/v, polylactic:glycolic acid 
ratio 50:50, molecular weight 34 kDa, carrying uncapped 
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hydroxyl and carboxyl, Boehringer Ingelheim, Ingelheim, 
Germany) and 10 mg of cationic lipid 1,2-dioleoyl-sn-
glycero-3-ethylphosphocholine (DOTAP, chloride salt, 
Avanti Polar Lipids Inc, Alabaster, AL) were dissolved in 
2.5 mL dichloromethane and injected through a needle 
(inner diameter 0.17 mm) under a turbulent regime (50 mL/
minute) onto a Pluronic F68® solution (500 µL 6% w/v, 
Sigma-Aldrich, St Louis, MO) containing 2 mg of either 
recombinant KMP-11 protein, non-recombinant pcDNA3, 
or recombinant pcDNA3-KMP-11. This W
1
/O emulsion 
was forced to circulate through the system for 4 minutes 
in order to homogenize the emulsion droplet size. The 
preformed emulsion was injected into the outer water (W
2
) 
phase, ie, 15 mL of polyvinyl alcohol 0.5% w/v (87% 
hydrolyzed, molecular weight 115,000; BDH Prolabo; VWR 
International, Radnor, PA) under a constant pump flow. The 
turbulent injection resulted in formation of a double emulsion 
(W
1
/O/W
2
) that was homogenized by circulation through the 
system for 8 minutes. The final emulsion was magnetically 
stirred to allow solvent evaporation and particle formation. 
The resulting particles (recombinant KMP-11-loaded, 
nonrecombinant pcDNA3-loaded, pcDNA3-KMP-11-loaded 
nanoparticles) or unloaded nanoparticles were centrifuged 
(9300 × g), washed, freeze-dried, lyophilized and stored at 
-20°C. Nanoparticle size and zeta potential were determined, 
respectively, by photon correlation spectroscopy and laser 
Doppler velocimetry using a Zetasizer Nano Series (Malvern 
Instruments, Worcestershire, UK) after dilution of the samples 
in distilled water or KCl (1 mM). All measurements were 
performed in triplicate. The recombinant KMP-11 protein 
content of the recombinant KMP-11-loaded nanoparticles 
was determined using the Micro BCA protein assay (Pierce, 
Rockford, IL) following the manufacturer’s instructions. The 
colorimetric reaction was measured in a spectrophotometer 
at 562 nm and compared with the absorbance obtained with 
nonencapsulated recombinant KMP-11. For this purpose, 
control calibration curves (1.5–50 µg/mL) were prepared 
using recombinant KMP-11 dissolved in NaOH 0.1 N. 
The amount of plasmidial pcDNA3-KMP-11 DNA or 
nonrecombinant pcDNA3 loaded into the nanoparticles was 
estimated using a fluorimetric assay (PicoGreen® dsDNA 
quantitation kit; Molecular Probes, Eugene, OR), following 
the manufacturer’s instructions. The amount of encapsulated 
recombinant KMP-11 in the nanoparticles was 3.5 ± 0.5 per mg 
of recombinant KMP-11-loaded particles; nonrecombinant 
pcDNA3-loaded nanoparticles contained 7.2 ± 0.7 µg of 
pcDNA3 per mg of particles, and pcDNA3-KMP-11-loaded 
nanoparticles contained 6.4 ± 1.2 µg of pcDNA3-KMP-11 
DNA per mg of particles.
Immunization with KMP-11 plasmid DNA 
or recombinant KMP-11-loaded PLGA 
nanoparticles
BALB/c mice (in groups of six) received 100 µg of 
 nonrecombinant pcDNA3 or pcDNA3-KMP-11 in saline into 
the right quadriceps on days 0, 14, and 28. Alternatively, mice 
were primed with pcDNA3-KMP-11-loaded nanoparticles 
(containing 30 µg of pcDNA3-KMP-11), injected into the 
left ear dermis, and were boosted 21 days later with recom-
binant KMP-11-loaded nanoparticles (containing 10 µg of 
recombinant KMP-11) in the presence of 25 µg of each 
CpG oligodeoxynucleotide (5′-TCAGCGTTGA-3′ and 
5′-GCTAGCGTTAGCGT-3′) (E-OLIGOS).31 Control mice 
were primed with nonrecombinant pcDNA3-loaded nano-
particles (containing 30 µg of pcDNA3), also injected in 
the left ear dermis, and were boosted with unloaded (empty) 
nanoparticles + CpG. Samples of immune sera were collected 
2 weeks after the last immunization.
Cytokine detection in mice immunized 
with KMP-11 plasmid DNA or 
with recombinant KMP-11-loaded 
nanoparticles
BALB/c mice were immunized as described above. Two 
weeks after the last immunization, the mice were euthanized, 
and single-cell suspensions of lymph nodes draining the 
immunization site (popliteal for DNA-injected mice and 
retroaxillary for PLGA nanoparticle-injected mice) were 
prepared aseptically. Briefly, the draining lymph nodes 
were homogenized in RPMI 1640 medium and the cells were 
resuspended in RPMI medium supplemented with 2 mM 
L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 
10% fetal calf serum (all from Invitrogen, Carlsbad, CA) and 
0.05 M β-mercaptoethanol. Cell suspensions were stimulated 
with recombinant KMP-11 (10 µg/mL) for 48 hours. Culture 
supernatants were harvested and the presence of cytokines 
was assayed using a Th1/Th2 cytokine cytometric bead array 
(BD Biosciences, Franklin Lakes, NJ), which detects murine 
IL-2, IL-4, IL-5, IFN-γ, and tumor necrosis factor-alpha 
(TNF-α), following the manufacturer’s instructions. Data 
were acquired and analyzed using a FACSort flow cytometer 
(BD Immunocytometry, San Jose, CA) and CBA analysis 
software (Becton-Dickinson, Franklin Lakes, NJ).
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humoral immune response in mice 
immunized with KMP-11 plasmid DNA 
or with recombinant KMP-11-loaded 
nanoparticles
Enzyme-linked immunosorbent assay microplates were 
coated overnight at 4°C with recombinant KMP-11 (1 µg/mL) 
in coating buffer (NaHCO
3
 0.45 M, Na
2
CO
3
 0.02 M, pH 
9.6). After washing with phosphate-buffered saline-Tween, 
the wells were blocked with phosphate-buffered saline-
Tween plus 5% dried skim milk for one hour at 37°C. The 
wells were incubated overnight with sera (diluted 1:100) 
from mice immunized with pcDNA3-KMP-11 only or with 
pcDNA3-KMP-11-loaded nanoparticles followed by recom-
binant KMP-11-loaded nanoparticles, in the presence of CpG. 
After further washings, wells were incubated with alkaline 
phosphatase-conjugated antimouse IgG antibody (Promega, 
Madison, WI) diluted (1:2500) in phosphate-buffered saline-
Tween, for one hour at 37°C. Following another washing 
cycle, wells were developed with p-nitrophenylphosphate 
in sodium carbonate buffer at pH 9.6 with 1 mg/mL of 
MgCl
2
. The absorbance was recorded at 405 nm. Serum IgG 
subclasses were determined using antimouse IgG1 or IgG2a 
alkaline phosphatase conjugates (Sigma-Aldrich).
Challenge with L. braziliensis and sand  
fly saliva
L. braziliensis promastigotes (strain MHOM/BR/01/
BA78832) were grown in Schneider medium (Sigma-Aldrich) 
supplemented with 100 U/mL of penicillin, 100 µg/mL of 
streptomycin, and 10% heat-inactivated fetal calf serum 
(all from Invitrogen). Stationary-phase promastigotes were 
used in all experiments. Adult Lutzomyia intermedia sand 
flies were captured in Corte de Pedra, Bahia, and used for 
dissection of salivary glands. Preparation of salivary gland 
sonicate was conducted as described elsewhere.33 The level of 
lipopolysaccharide contamination of salivary gland sonicate 
preparations was determined using a commercially available 
Limulus amebocyte lysate chromogenic kit (QCL-1000, 
Lonza Biologics, Newington, NH); the lipopolysaccharide 
concentration was ,0.1 ng/mL. Two weeks after the last 
immunization, all groups of mice were challenged in the 
dermis of the right ear with L. braziliensis promastigotes + 
salivary gland sonicate, as described earlier.34 The progress 
of infection was monitored weekly, for 10 weeks, by measur-
ing of ear swelling with a digital caliper (Thomas Scientific, 
Swedesboro, NJ). Parasite load in the infected ear and in its 
draining lymph nodes was determined as described below.
Parasite load estimate
Parasite load was determined using a quantitative limiting-
dilution assay as described elsewhere.32 Briefly, infected 
ears and lymph nodes draining the infection site were 
aseptically excised at five weeks following infection with 
L. braziliensis + salivary gland sonicate and homogenized 
in Schneider medium (Sigma-Aldrich). The homogenates 
were serially diluted in Schneider medium supplemented as 
before and seeded into 96-well plates containing biphasic 
blood agar (Novy-Nicolle-McNeal) medium. The number 
of viable parasites was determined from the highest dilution 
at which the promastigote could be grown out after up to 
2 weeks of incubation at 25°C.
Evaluation of cellular immune response 
after challenge by flow cytometry
Five weeks following infection with L. braziliensis + salivary 
gland sonicate, the mice were euthanized, and single-cell 
suspensions of lymph nodes draining the infection site were 
prepared as described above. Cells were activated in the 
presence of anti-CD3 10 µg/mL and anti-CD28 10 µg/mL 
or with Con A 5 µg/mL (Amersham Biosciences, Piscataway, 
NJ), and were later incubated with Brefeldin A 10 µg/mL 
(Sigma-Aldrich). Cells were blocked with anti-Fc receptor 
antibody (2.4G2) and were double-stained simultaneously 
with antimouse surface CD4 (H129.19) conjugated to 
FITC. For intracellular staining of cytokines, cells were 
permeabilized using Cytofix/Cytoperm (BD Biosciences) 
and incubated with the anticytokine antibodies conjugated 
to PE:IFN-γ (XMG1.2), IL-4 (BVD4-1D11), and IL-10 
(JES5-16E3). The isotype controls used were rat IgG2b 
(A95-1) and rat IgG2a (R35-95). Data were collected and 
analyzed using CELLQuest software and a FACSort flow 
cytometer (Becton-Dickinson). The steady-state frequencies 
of cytokine positive cells were determined using lymph node 
cells from control mice.
Cytokine expression at challenge site
Five weeks following infection with L. braziliensis + salivary 
gland sonicate, the mice were euthanized, infected ears 
were excised and placed into RLT buffer, and total RNA 
was extracted using the RNeasy Protect Mini Kit (Qiagen) 
according to the manufacturer’s instructions. Ear tissue was 
mechanically lysed with ceramic beads in a MagNALyzer® 
instrument (Roche Molecular Systems, Pleasanton, CA), 
according to the manufacturer’s instructions. The resulting 
tissue lysates were then employed in downstream total RNA 
extraction. The resulting RNA was resuspended in 20 µL 
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of water and stored at -80°C until use. cDNA synthesis 
was performed after reverse transcription (Im Prom-II™ 
reverse transcription system; Promega) of RNA. Real-time 
polymerase chain reaction was performed in triplicate on 
the ABI Prism 7500 (Applied Biosystems, Foster City, CA); 
thermal cycle conditions consisted of a two-minute initial 
incubation at 50°C followed by ten-minute denaturation 
at 95°C, and 50 cycles at 95°C for 15 seconds and 60°C 
for one minute each. Each sample and the negative control 
were analyzed in triplicate for each run. The comparative 
method was used to analyze gene expression. Cytokine cycle 
threshold (C
t
) values were normalized to GAPDH expression, 
as determined by ∆C
t
 = C
t (cytokine)
 – C
t (GAPDH)
. Fold change was 
determined by 2–∆∆Ct, where ∆∆C
t
 = ∆C
t (experimental)
 – ∆C
t (control).
35 
The primers employed herein are described elsewhere.33
Statistical analysis
Data are presented as the mean ± the standard error. The 
significance of the results was calculated using nonparametric 
statistical tests, ie, the two-sided Mann-Whitney test for 
comparisons between two groups. Analyses were conducted 
using Prism software (version 5.0; GraphPad Software, Inc, 
San Diego, CA). Differences were considered statistically 
significant at P # 0.05.
Results
Cellular immune response after 
immunization with plasmid DNA ± 
recombinant PLGA nanoparticles
Initially we investigated the anti-KMP-11 cellular immune 
response induced by immunization using the different strategies. 
As shown in Figure 1, in vitro stimulation of draining lymph 
node cells from mice immunized with pcDNA3-KMP-11 
induced a significantly higher production of IL-2 (Figure 1A), 
IFN-γ (Figure 1B), TNF-α (Figure 1C), IL-4 (Figure 1D), and 
IL-5 (Figure 1E), when compared with control mice.
The recombinant nanoparticles used herein had a mean 
size of 300–450 nm, irrespective of the type of encapsulated 
antigen (DNA or protein). The mean zeta potential values 
were between 20 mV and 30 mV, indicating a positive 
charge at pH 7.4, and independently of the nanoparticle 
load (recombinant KMP-11 or pcDNA3-KMP-11). Recom-
binant KMP-11 content per mg of recombinant particle was 
3.5 ± 0.5 µg. Regarding plasmid DNA content, one mg of 
recombinant particles contained 7.2 ± 0.7 µg and 6.4 ± 1.2ug 
of wild-type and pcDNA3-KMP-11, respectively. When 
mice were immunized with the recombinant nanoparticle 
formulations, IL-2 (Figure 2A) and IFN-γ (Figure 2B) pro-
duction was also increased. However, in this case, TNF-α 
levels were significantly higher (Figure 2C), whereas IL-4 
(Figure 2D) and IL-5 (Figure 2E) production was similar to 
that detected in control mice.
humoral immune response on 
immunization with plasmid DNA  
or PLGA nanoparticles
We also probed for the anti-KMP-11 humoral immune 
response induced by immunization with the different strate-
gies. We did not detect anti-KMP-11 antibodies in mice 
immunized with either pcDNA3-KMP-11 or with nonrecom-
binant pcDNA3 (data not shown). However, mice inoculated 
with pcDNA3-KMP-11-/recombinant KMP-11-loaded 
nanoparticles + CpG developed a strong and antigen-specific 
humoral immune response (Figure 3A). IgG1 and IgG2a 
subclasses (Figure 3B) were detected in immune sera which 
could be associated with the presence of both IL-4/IL-5 and 
IFN-γ/TNF-α, as seen upon restimulation of draining lymph 
node cells (Figure 2).
Outcome of L. braziliensis infection  
in mice immunized with plasmid DNA  
or PLGA formulations
Next, we investigated the outcome of infection with 
L. braziliensis, in the presence of sand fly saliva. Immunization 
with pcDNA3-KMP-11 did not alter the course of clinical 
disease upon a live challenge (Figure 4A), with both 
immunized and control mice displaying the same outcome 
followed by spontaneous healing. However, mice inoculated 
with pcDNA3-KMP-11 had a significantly lower (P , 0.05) 
parasite load at the ear dermis 5 weeks after infection when 
compared with control mice (Figure 4B). A similar finding 
was observed in draining lymph nodes (Figure 4C), although 
the difference was not significant.
Interestingly, immunization with pcDNA3-KMP-11-/
recombinant KMP-11-loaded nanoparticles + CpG also 
did not prevent development of disease (Figure 5A) when 
compared with control animals. Of note, the ear thickness of 
mice immunized with recombinant nanoparticles was slightly 
smaller when compared with controls (Figure 5A) at 5 weeks 
after infection. Similar to results obtained upon DNA immu-
nization (Figure 4B), immunization with the recombinant 
formulations also significantly (P , 0.05) decreased parasite 
load in the ear dermis (Figure 5B). Interestingly, parasite load 
in draining lymph nodes was also lower when compared with 
control mice (Figure 5C).
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Cytokine production in situ after  
L. braziliensis + salivary gland sonicate 
challenge
Because both immunization strategies significantly reduced 
parasite load at the infection site, we probed for cytokine 
expression therein 5 weeks after infection. Remarkably, mice 
immunized with pcDNA3-KMP-11 showed upregulation in 
both IFN-γ and IL-10 expression (Figure 6A) at the infection 
site; IFN-γ expression was upregulated by approximately 5-fold 
in comparison with control animals, whereas this increase was 
about 15-fold for IL-10. TNF-α expression was not detected 
in mice immunized with pcDNA3-KMP-11. On the other 
hand, mice immunized with pcDNA3-KMP-11-/recombinant 
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Figure 1 Cytokine production in mice immunized with a plasmid DNA encoding KMP-11.  
Notes: BALB/c mice were immunized with nonrecombinant pcDNA3 (open bars) or with pcDNA3-KMP-11 (closed bars), as described. Two weeks after the last 
immunization, draining lymph nodes were collected and the cells were restimulated with recombinant KMP-11. The presence of cytokines in culture supernatants was 
determined by flow cytometry, using a Th1–Th2 cytometric bead array. Data are presented as the mean ± standard error and are from two independent experiments, each 
performed with six mice per group. *P , 0.05. 
Abbreviations: IFN, interferon; IL, interleukin; KMP-11, kinetoplastid membrane protein-11; TNF, tumor necrosis factor.
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KMP-11-loaded nanoparticles + CpG showed a more moderate 
upregulation in IFN-γ and TNF-α expression (Figure 6B) at 
the infection site. In contrast with mice immunized using 
pcDNA3-KMP-11, challenge infection with parasites induced 
downregulation in IL-10 expression in the mice receiving 
recombinant PLGA nanoparticles (Figure 6B).
Upon challenge with L. braziliensis + salivary gland 
sonicate, mice immunized with pcDNA3-KMP-11 or with the 
recombinant nanoparticle formulations also displayed a lower 
parasite load within the draining lymph nodes (Figure 4C and 
5C, respectively). Therefore, we also evaluated the frequency of 
cytokine-secreting cells therein. After infection, mice immunized 
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Figure 2 Cytokine production in mice immunized with KMP-11-loaded nanoparticles. 
Notes: Control BALB/c mice were immunized with nonrecombinant pcDNA3-loaded nanoparticles followed by unloaded (empty) nanoparticles + CpG (open bars). 
Experimental BALB/c mice were immunized with pcDNA3-KMP-11-loaded nanoparticles followed by recombinant KMP-11-loaded nanoparticles + CpG (closed bars). 
Two weeks after the last immunization, draining lymph nodes were collected and cells were restimulated with recombinant KMP-11. The presence of cytokines in culture 
supernatants was determined by flow cytometry, using a Th1–Th2 cytometric bead array. Data are presented as the mean ± standard error and are from two independent 
experiments, each performed with six mice per group. *P , 0.05. 
Abbreviations: IFN, interferon; IL, interleukin; KMP-11, kinetoplastid membrane protein-11; TNF, tumor necrosis factor.
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Figure 3 humoral immune response in mice immunized with KMP-11-loaded nanoparticles.  
Notes: Control BALB/c mice were immunized with nonrecombinant pcDNA3-loaded nanoparticles followed by unloaded nanoparticles + CpG (open bars). Experimental 
BALB/c mice were immunized with pcDNA3-KMP-11-loaded nanoparticles followed by recombinant KMP-11-loaded nanoparticles + CpG (closed bars). (A) Presence of 
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with pcDNA3-KMP-11 displayed a lower percentage of CD4+ 
IFN-γ+ (Figure 7A), CD4+ IL-4+ (Figure 7B), and CD4+ IL-10+ 
(Figure 7C) cells when compared with controls.
Cells from mice immunized with pcDNA3-KMP-11-/
recombinant KMP-11-loaded nanoparticles + CpG also 
displayed a decreased frequency of CD4+ IFN-γ+ T cells 
(Figure 8A), after infection. In these animals, the percent-
age of CD4+ IL-4+ (Figure 8B) and CD4+ IL-10+ cells 
(Figure 8C) was similar (Figure 7B) or slightly higher 
(Figure 7C) when compared with controls. Similar results 
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were found for cytokine-secreting CD8+ T cells (data 
not shown).
Discussion
In the present work, we evaluated two immunization strate-
gies for their potential to elicit protective immune responses 
in an experimental model of infection. One strategy consisted 
of immunization with plasmid DNA and the other involved 
use of PLGA nanoparticles loaded with plasmid DNA or 
with the respective recombinant protein. We hypothesized 
that encapsulation would protect the antigen from degrada-
tion and, in parallel, that a heterologous prime-boost strategy 
would enhance the immune response.
Herein, immunization of BALB/c mice with a plasmid 
DNA coding for L. infantum chagasi KMP-11 elicited a mixed 
Th1/Th2-type immune response. However, immunization 
with the recombinant nanoparticle formulations, in the 
presence of CpG, induced a significant increase in TNF-α 
upon restimulation in vitro. Indeed, nanoparticles formulated 
with DOTAP, the cationic lipid used here, promote a 
proinflammatory response, with presence of IL-2, IFN-γ, 
TNF-α,36 and oligodeoxynucleotides, such as CpG motifs, 
are able to trigger plasmacytoid dendritic cells, resulting in 
TNF-α production.37 Use of DOTAP in our formulations 
and of CpG in our immunization scheme may therefore 
explain the elevated TNF-α levels in immunized mice. We 
also detected the presence of IgG1 and IgG2a antibodies 
(Figure 3), suggesting participation of both IL-4 and IFN-γ 
in antibody isotype switching, even though levels of these 
cytokines were not significantly increased in mice immunized 
with PLGA nanoparticles (Figure 2).
Following immunization, the mice were challenged 
with live parasites in the presence of sand fly saliva, 
mimicking the context of natural infection with 
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Notes: Control BALB/c mice were immunized with nonrecombinant pcDNA3-loaded nanoparticles followed by unloaded nanoparticles + CpG (open bars). Experimental 
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(A). Parasite load in the ear (B) and in draining lymph nodes (C) was determined 5 weeks following infection. Data are presented as the mean ± standard error and are from 
two experiments. *P , 0.05. 
Abbreviations: KMP-11, kinetoplastid membrane protein-11; SGS, salivary gland sonicate.
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Leishmania spp. Upon challenge, neither immunization 
strategy  prevented lesion development. Air pouch stimulation 
with L. braziliensis + L. intermedia saliva enhances CXCL10, 
CCL2, TNF-α, and IL-10 expression,33 confirming the 
immunomodulatory role of saliva from L. intermedia. 
Although we did not probe for the protective capacity of our 
immunization strategies in the absence of sand fly saliva, we 
may speculate that salivary molecules at the time of parasite 
challenge may have modulated the microenvironment, favor-
ing lesion development.
Despite the inability of the present immunization strate-
gies to prevent disease manifestation, a significant reduction 
in parasite load was detected at the challenge site. Mice 
immunized with either DNA alone or with recombinant 
PLGA nanoparticles displayed increased IFN-γ expres-
sion at the infection site. Moreover, mice immunized with 
recombinant PLGA nanoparticles + CpG also showed 
elevated TNF-α. IFN-γ and TNF-α act in concert to acti-
vate inducible nitric oxide synthase for the production of 
nitric oxide, and TNF-α stimulates macrophages to produce 
nitric oxide.6 We can suggest that, in the group immunized 
with recombinant PLGA nanoparticles, upregulation of 
IFN-γ and TNF-α combined with downregulation of IL-10, 
may explain the greater parasite killing at the challenge 
site. In mice immunized with DNA alone, upregulation of 
IFN-γ expression was also observed but was accompanied 
by a strong elevation of IL-10 expression. Mononuclear 
cells from patients with leishmaniasis produced high levels 
of IL-10 upon stimulation with recombinant KMP-11,38 
whereas addition of recombinant KMP-11 to cells previously 
stimulated with soluble Leishmania antigen decreased IFN-γ 
secretion.39 We could speculate that the immune response 
induced in DNA-immunized mice may have been more 
prone to modulation exerted by parasite-derived KMP-11 
compared with the response elicited by immunization with 
PLGA nanoparticles.
Parasite load in the draining lymph nodes was also 
lower following immunization with either DNA alone 
or with recombinant PLGA nanoparticles, although 
differences between the experimental and control groups 
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were not significant. One could consider that migration of 
the effector T cell population (CD4+ IFN-γ+) to the infec-
tion site, with parasite killing, explains the lower frequency 
of cytokine-secreting CD4+ cells in mice immunized with 
plasmid DNA or with PLGA nanoparticles, when compared 
with the respective controls. Of note, parasites persist in 
draining lymph nodes of BALB/c mice inoculated with 
L. braziliensis,32 despite resolution of dermal lesions and 
parasite clearance from the infection site. Parasite persistence 
in cutaneous leishmaniasis has been associated with the pres-
ence of regulatory T cells.40 Therefore, another possibility 
concerns the presence of regulatory T cells within draining 
lymph nodes preventing parasite clearance. In the draining 
lymph nodes, these regulatory T cells could counteract the 
presence of effector cells. Indeed, in mice immunized with 
PLGA nanoparticles, the frequency of CD4+ IL-10+ T cells 
was elevated in draining lymph nodes.
A stronger immune response is elicited when antigen 
is associated with particles, compared with soluble antigen 
alone.41 In the case of leishmaniasis, immunization CpG and 
PLGA nanospheres loaded with autoclaved L. major was able 
to decrease L. major infection and this effect was associated 
with increased IFN-γ and decreased IL-4 production.21 Doroud 
et al showed that immunization with solid lipid nanoparticles 
loaded with plasmid DNA coding for Leishmania cysteine 
proteinase conferred protection against L. major,42 and was 
associated with increased IFN-γ levels before challenge and 
an elevated ratio of IFN-γ/IL-5 after challenge. In addition 
to the choice of antigen and experimental model, several 
variables such as particle chemistry, size, and surface charge, 
affect the ensuing immune response,43,44 and may explain the 
different outcomes observed in terms of immunity against 
leishmaniasis. Of note, we performed experiments in which 
mice were immunized with naked DNA coding for KMP-11 
and were boosted with recombinant KMP-11 + CpG. 
 Following this strategy, mice did not develop a strong humoral 
immune response, nor was parasite load decreased following 
a challenge with live parasites (data not shown). Therefore, we 
can suggest that antigen encapsulation enhanced efficacy of 
the immune response, possibly by protecting the antigen from 
rapid degradation and or by ascertaining uptake by antigen-
presenting cells, as seen in the present results.
Antigens that have proven effective against L. major, such 
as LACK, LbSTI1, LeIF, and TSA, have not induced similar 
responses when tested against L. braziliensis.45 Vaccination 
with soluble L. major promastigote exogenous antigens con-
ferred protection against L. donovani but also failed to induce 
a similar response against L. braziliensis.46 Since the current 
findings highlight the need to probe actively for antigens and 
strategies capable of preventing cutaneous leishmaniasis 
caused by L. braziliensis, we believe recombinant nanopar-
ticles comprise a platform tailored for such discoveries.
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